Adaptimmune Therapeutics (NASDAQ:ADAP) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Monday, February 4th.
Several other research analysts have also recently issued reports on ADAP. SunTrust Banks lowered their price objective on Adaptimmune Therapeutics to $12.00 and set a “buy” rating for the company in a research report on Thursday, December 13th. Zacks Investment Research raised Adaptimmune Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a research report on Monday, February 4th. Cowen reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics in a research report on Tuesday, November 6th. Finally, ValuEngine cut Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $13.50.
Shares of ADAP stock traded up $0.18 on Monday, hitting $4.57. The stock had a trading volume of 230,242 shares, compared to its average volume of 211,820. Adaptimmune Therapeutics has a 1 year low of $3.60 and a 1 year high of $14.63. The company has a market capitalization of $431.50 million, a PE ratio of -4.76 and a beta of 1.37.
In other Adaptimmune Therapeutics news, Director Lawrence M. Alleva bought 47,280 shares of the business’s stock in a transaction dated Monday, December 17th. The stock was acquired at an average cost of $0.84 per share, with a total value of $39,715.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Over the last three months, insiders have sold 9,897 shares of company stock valued at $53,147. Company insiders own 26.47% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Raymond James & Associates increased its stake in Adaptimmune Therapeutics by 59.0% in the 4th quarter. Raymond James & Associates now owns 22,906 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 8,498 shares in the last quarter. FDx Advisors Inc. acquired a new stake in Adaptimmune Therapeutics during the 3rd quarter valued at $142,000. B. Riley Wealth Management Inc. acquired a new stake in Adaptimmune Therapeutics during the 3rd quarter valued at $148,000. BlackRock Inc. grew its holdings in Adaptimmune Therapeutics by 1.6% during the 3rd quarter. BlackRock Inc. now owns 775,405 shares of the biotechnology company’s stock valued at $10,514,000 after buying an additional 12,113 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in Adaptimmune Therapeutics by 157.3% during the 4th quarter. SG Americas Securities LLC now owns 20,004 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 12,229 shares during the last quarter. 67.96% of the stock is owned by hedge funds and other institutional investors.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.